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ARTICLE OPEN
A pragmatic randomized waitlist-controlled effectiveness and
cost-effectiveness trial of digital interventions for depression
and anxiety
Derek Richards 1,2✉, Angel Enrique 1,2, Nora Eilert1,2, Matthew Franklin 3, Jorge Palacios1,2, Daniel Duffy 1,2, Caroline Earley1,2,
Judith Chapman4, Grace Jell4, Sarah Sollesse4 and Ladislav Timulak 1
Utilization of internet-delivered cognitive behavioural therapy (iCBT) for treating depression and anxiety disorders in stepped-care
models, such as the UK’s Improving Access to Psychological Therapies (IAPT), is a potential solution for addressing the treatment
gap in mental health. We investigated the effectiveness and cost-effectiveness of iCBT when fully integrated within IAPT stepped-
care settings. We conducted an 8-week pragmatic randomized controlled trial with a 2:1 (iCBT intervention: waiting-list) allocation,
for participants referred to an IAPT Step 2 service with depression and anxiety symptoms (Trial registration: ISRCTN91967124). The
primary outcomes measures were PHQ-9 (depressive symptoms) and GAD-7 (anxiety symptoms) and WSAS (functional impairment)
as a secondary outcome. The cost-effectiveness analysis was based on EQ-5D-5L (preference-based health status) to elicit the
quality-adjust life year (QALY) and a modified-Client Service Receipt Inventory (care resource-use). Diagnostic interviews were
administered at baseline and 3 months. Three-hundred and sixty-one participants were randomized (iCBT, 241; waiting-list, 120).
Intention-to-treat analyses showed significant interaction effects for the PHQ-9 (b=−2.75, 95% CI −4.00, −1.50) and GAD-7
(b=−2.79, 95% CI −4.00, −1.58) in favour of iCBT at 8-week and further improvements observed up to 12-months. Over 8-weeks
the probability of cost-effectiveness was 46.6% if decision makers are willing to pay £30,000 per QALY, increasing to 91.2% when
the control-arm’s outcomes and costs were extrapolated over 12-months. Results indicate that iCBT for depression and anxiety is
effective and potentially cost-effective in the long-term within IAPT. Upscaling the use of iCBT as part of stepped care could help to
enhance IAPT outcomes. The pragmatic trial design supports the ecological validity of the findings.
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INTRODUCTION
Stepped-care models have been proposed as a potential solution1
to bridge the substantial gap between the prevalence of common
mental health disorders, including depression and anxiety, and
the access rates for evidence-based treatments2,3. Stepped-care
seeks to up-scale treatment initiatives by matching treatment
intensity and duration to clients’ presenting needs, thereby
optimizing outcomes and service capacity utilization. Investing
in upscaling initiatives for mental health treatments is projected to
produce large returns at a benefit-to-cost ratio of 3.3–5.7 to 1
when accounting for economic benefits and the value of health
returns4. The Improving Access to Psychological Therapies (IAPT)
programme in the UK is one of the first examples of a mental
health stepped-care model implemented nationwide5.
IAPT services offer evidence-based treatments to individuals
experiencing depression and/or anxiety, providing low-intensity
interventions alongside traditional treatments (e.g. face-to-face
therapy)5. Specifically, at Step 2, low-intensity interventions are
offered to patients presenting with mild to moderate depression
and anxiety symptoms, while those with more severe or complex
presentations of depression and anxiety are assigned to step 3
high-intensity treatments. Low-intensity interventions include
empirically established treatments like guided bibliotherapy and
internet-delivered cognitive behavioural therapy (iCBT). Similar
multicomponent models of care exist in other countries, such as
the collaborative care models in the USA6. A key aspect of IAPT is
routine outcome monitoring, which is used to improve individual
clinical outcomes by aiding ongoing treatment decisions, but also
to establish publicly available service-level clinical performance
reports7. In the period 2018–19, IAPT received 1.6 million new
referrals, of which 1.09 million were seen at least once for
assessment and guidance and 582,556 received a course of
therapy (defined as two or more sessions)8.
Political and policy initiatives that helped establish IAPT
promised significant economic benefits, claiming that making
evidence-based psychological treatments available would have no
net cost to the Treasury9, yet envisioned economical returns from
IAPT remain debated10. Internet-delivered interventions may be
one way to improve IAPT outcomes in a cost-effective way11.
However, currently iCBT accounts for only 7% of treatments
completed within IAPT8. Clark et al. found that amongst services
that achieve lower treatment rates, engaging more users in
treatment could improve recovery and reliable improvement by
33% and 90%, respectively7, highlighting the potential for
increased use of iCBT within IAPT to help achieve this aim.
Generally, iCBT for depression and anxiety has been found to
significantly reduce symptoms and produce medium to large
effect sizes at post-treatment, with a maintenance of effects at
follow-up12. As a result, iCBT has established itself as a viable
mode of treatment for depression and anxiety. Still, most research
has explored iCBT’s efficacy under more controlled settings, with
effectiveness trials in routine care finding mixed outcomes12,13.
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Most effectiveness trials were situated in specialized iCBT clinics.
Research to assess iCBT’s effectiveness in non-specialized settings
is scarce. In the UK, iCBT has previously been investigated within a
primary care context (the REEACT trials)13,14. Outcomes from these
trials were discouraging, finding iCBT to be neither more effective
nor cost-effective than treatment as usual by general practitioners
alone. Implementation challenges resulting in low up-take and
usage of iCBT and less than optimal support provided during
treatment (i.e. only minimal or non-therapeutic support when
research emphasises the superiority of supported-iCBT)15 likely
affected the trials’ outcomes.
We sought to evaluate the effectiveness and cost-effectiveness
of iCBT for depression and anxiety in a pragmatic clinical trial
within IAPT routine stepped care. We hypothesized that iCBT
would reduce anxiety and depression severity over an 8-week
treatment period compared to waiting-list control and be
considered cost-effective based on criteria set out by the National
Institute for Health and Care Excellence (NICE; UK). Effectiveness
and cost-effectiveness were hypothesized to be maintained
throughout follow-up.
RESULTS
Baseline characteristics
Between 28 June 28 2017 and 30 April 2018, 464 participants were
invited to the trial. Of those, 430 consented to the trial and 361
(84%) met all inclusion criteria and were randomized. Retention of
participants for research purposes was highest at 8-weeks
(intervention-arm: 82%; control-arm: 76%) and lowest at 12-
months (intervention-arm: 72%; Fig. 1). The median age of
participants was 29 (IRQ= 18) and 70% (258/361) were female
(Table 1). At baseline, 80% (290/361) met criteria for at least one M.
I.N.I.7.0.2 diagnosis and 70% (252/361) were at ‘caseness’ (defined
thresholds as set by IAPT being PHQ-9 ≥ 10 and/or GAD7 ≥ 8) on
both PHQ-9 and GAD-7 (Table 1).
Effectiveness outcomes
Outcomes at post-treatment. In evaluating primary study out-
comes, 8-week models suggested significant interaction effects of
time-by-intervention-arm for PHQ-9 (b=−2.75; SE= 0.64; 95% CI
−4.00, −1.50; p < 0.0001; observed power 0.99) and GAD-7 (b=
−2.79; SE= 0.61; 95% CI −4.00, −1.58; p < 0.0001; observed power
0.99). Paired comparisons indicated that in those who received
iCBT, depression and anxiety symptoms were reduced from
baseline to 8-weeks more than in those who did not (Fig. 2 and
Supplementary Table 1 for further details). Table 2 shows
observed and estimated means for each group and timepoint.
Utilizing the same model as above, there was a significant time-
by-intervention-arm effect for the WSAS (b=−2.65, SE= 0.99,
95% CI −4.59, −0.72; p= 0.075; observed power 0.77) and
significantly lower functional impairment in the intervention-arm
at 8 weeks.
Follow-up outcomes
Follow-up models demonstrated maintained or improved symp-
tom levels across all follow-up time-points (Fig. 3). Paired
comparisons confirmed significant improvements from 8-weeks
to 12-months on PHQ-9 (mean difference 3.12; SE= 0.44; 95% CI
1.82, 4.39; p < 0.0001), GAD-7 (mean difference 2.60; SE= 0.40;
95% CI 1.43, 3.76; p < 0.0001) and WSAS (mean difference 3.24;
SE= 0.62; 95% CI 1.40, 5.07; p < 0.0001; see Supplementary Table 2
for model coefficients and Table 2 for observed and estimated
means across measures).
Clinically significant change
At post-treatment (8-week), 46.4% (90/194) of the intervention-
arm relative to 16.7% (15/90) control-arm participants recovered,
with 63.4% (123/194) intervention-arm relative to 34.4% (31/90)
control-arm participants showing reliable improvement. Reliable
recovery in the intervention-arm was 40.7% (79/194), and 13.3%
(12/90) in the control arm. All between-group differences were
significant (p < 0.01). Amongst 3-month M.I.N.I.7.0.2 completers
(n= 179), 60% (18/30) with depression, 50% (24/48) with anxiety,
and 46% (30/65) with comorbid depression and anxiety diagnoses,
did not meet diagnostic criteria anymore at 3-months. Overall,
56.4% (101/179) of participants did not meet diagnostic criteria for
any disorder at 3-months (see Supplementary Tables 3 and 4 for
details).
Platform usage
In terms of usage of the platform by 8-weeks, participants had on
average 13.1 logins (SD= 10.8, median= 11, IQR= 12), used an
activity 94.2 times (SD= 90.1, median= 68, IQR= 115 25), spent
3 h 58min on the platform (SD= 219 min, median= 204min, IQR
= 220 5min) and completed 41% of the programme (SD= 0.24,
median 38%, IQR= 36%). By 12 months, the average usage
increased up to 22.3 logins (SD= 17.9, median 18, IQR= 17.75),
used an activity 126.1 times (SD= 133.3, median= 98, IQR:
130.75), 5 h 55 min spent (SD= 336 min, median= 295 min, IQR:
323.53 min) and 56% of the programme completed (SD= 0.29,
median 61%, IQR= 48%). Participants received an average of 4.7
online reviews (SD= 2.4, median= 5, IQR= 2.75).
Cost-effectiveness
In terms of preference-based health status, the EQ-5D-5L tariff
score in the ITT analysis suggest a sustained health improvement
over 12 months relative to baseline for those using iCBT, and at a
higher magnitude relative to control at 8-weeks (Supplementary
Tables 5 and 6). To give an indication of reported resource-use and
associated costs, descriptive statistics (i.e. response rates, resource-
use, and associated costs) by trial-arm in both, Complete-Case and
ITT, analyses are presented in Supplementary Tables 7–9.
The incremental CEA and within trial-group results are
presented in Supplementary Tables 10 and 11. Figure 4 presents
the cost-effectiveness acceptability curve suggesting probability
of iCBT cost-effectiveness dependent on willingness-to-pay per
QALY, by time-horizon of the baseline-adjusted analyses. The
base-case CEA (baseline-adjusted costs/baseline-adjusted QALYs)
suggests over 8-weeks, iCBT has a high probability of producing
QALY gains (>96.6%), but low probability of cost-savings (<0.5%),
at an estimated iCBT intervention cost of £94.63 per person
(Supplementary Table 12) against the no-intervention-cost
waiting-list control. Across base-case analyses, probability of
cost-effectiveness at NICE’s upper £30,000 per QALY threshold
ranged from 46.6% (baseline-adjusted QALY and baseline-
adjusted costs ITT analysis; ICER= £29,764) to 65.5% (unadjusted
ITT analysis; ICER= £20,310); however, these probabilities
decrease as the willingness-to-pay threshold decreases e.g.
21.0–47.9% within the same aforementioned analyses at NICE’s
lower £20,000 per QALY threshold over 8-weeks.
In the scenario analyses at 6, 9 and 12 months, the probability
of cost-effectiveness increases as the time horizon increases
(Fig. 4). The probability of cost-effectiveness at 12-months ranges
from 91.2% to 92.0% at £30,000, or 88.5–90.1% at £20,000, per
QALY gained dependent on analysis conducted (Fig. 4 only shows
baseline-adjusted costs/baseline-adjusted QALYs). An interpreta-
tion of these scenario analyses relative to base-case results is
provided in the Supplementary (section 4).
D. Richards et al.
2
npj Digital Medicine (2020)    85 Scripps Research Translational Institute
1
2
3
4
5
6
7
8
9
0
()
:,;
Adverse effects
Adverse effects were rare. Amongst 8-week measure completers,
5.2% (10/194) in the intervention-arm and 12.2% (11/90) in the
waiting-list deteriorated (i.e. increases of PHQ-9 ≥ 6 and/or GAD-7≥ 4).
Amongst those who completed the M.I.N.I.7.0.2 at 3 months, 4.47%
(8/179) moved from subthreshold symptoms of anxiety and/or
depression at baseline to a clinical diagnosis at 3 months. No
severe adverse events were reported. During follow-up, 55/241
Fig. 1 Flowchart of participants – CONSORT. CBT Cognitive Behavioural Therapy; GSH Guided Self-Help; MINI Mini International
Neuropsychiatric Interview 7.0.2 (M.I.N.I.7.0.2); PHQ-9 Patient-Health Questionnaire-9; GAD-7 Generalised Anxiety Disorder-7; S2 Step 2 IAPT;
S3 step 3 IAPT; PWP Psychological Wellbeing Practitioners; TS1 Telephone Screening 1.
D. Richards et al.
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intervention-arm participants (25.70%) either self-reported or were
recorded by IAPT to have received further mental health
treatment (Supplementary Table 13).
DISCUSSION
This large-scale RCT conducted within IAPT showed that iCBT for
depression and anxiety is effective as a standalone intervention
when fully integrated and operated in non-specialised routine
stepped-care settings. The pragmatic trial design increases the
ecological validity of the observed effectiveness of iCBT for
depression and anxiety. The primary hypothesis of the study was
confirmed by showing iCBT to be effective at the end of the 8-week
intervention period compared to waiting-list control, with further
statistically significant improvements in the primary outcomes over
the 12-month follow-up. The probability of cost-effectiveness was
predicted to be much higher over longer time-horizons than that
observed over the 8-week treatment period alone, driven by QALY-
based health improvement, which in part aligns with our clinical
and longer-term cost-effectiveness hypotheses.
The results build upon prior effectiveness evidence of
supported iCBT interventions for individuals with depression and
anxiety disorders in primary care12,15. The observed effects also
align with previous reviews in terms of the type of comparator,
where waitlists comparators lead to larger effects that when
compared to treatment as usual12. In the context of UK’s primary
care, the observed effects outperform the findings of the REEACT
trials13,14, which could be explained by the stepped-care model
within which these interventions were embedded, with contextual
factors favouring the deployment and uptake of the interventions
(i.e. trained personnel for the use of iCBT, routine outcome
monitoring). The significant improvements on depression and
anxiety symptoms observed in the follow-up compared to the end
of treatment period have also been shown in prior reviews12,15. In
addition, the statistically significant improvement in functional
impairment is coherent with the intervention’s effects on
depression and anxiety16.
Regarding clinical diagnoses, in the current study between 46%
and 60% of individuals did not meet diagnostic criteria anymore
for one or multiple diagnoses after receiving the iCBT intervention,
which is comparable to rates observed in previous studies of
iCBT17. In this regard, the rates of recovery from diagnosis align
with the rates of reliable improvement and recovery as assessed
using the primary outcomes. It is important to consider that in our
calculations of clinical improvement, we did not rely on the
continuous assessments from the IAPT routine outcome monitor-
ing system but we used different methods to account for missing
data5. Therefore, our outcomes are not directly comparable to
publicly reported IAPT outcomes as they are calculated differently.
Over 8 weeks, the baseline-adjusted ITT cost-effectiveness result
suggests an ICER of £29,764 which is below the £30,000 per QALY
NICE ICER upper threshold. This produced a probability of cost-
effectiveness of 46.6% due to the skewed nature of the estimates
driven by a high probability of QALY gains, but low probability of
Table 1. Baseline characteristics of study sample.
No. (%) Difference statistics
and p values
Overall (N= 361) Intervention-arm
(N= 241)
Waitlist control-arm
(N= 120)
Age, Median (IQR) 29 (18) 29 (19) 31 (18) U= 13273; p= 0.20
Female sex 258 (70.6%) 173 (71.8%) 85 (70.8%) χ2= 0.04; p= 0.90
White ethnicity 304 (84.2%) 206 (85.5%) 98 (81.7%) χ2= 15.07; p= 0.52
Religion
No religious affiliation 221 (63.0%) 156 (66.7%) 65 (55.6%) χ2= 10.64; p= 0.22
Christian 88 (25.1%) 54 (23.1%) 34 (29.1%)
Other 52 (14.4%) 31 (12.9%) 21 (17.5%)
Sexual orientation
Heterosexual 307 (90.3%) 209 (92.1%) 98 (86.7%) χ2= 4.41; p= 0.35
Lesbian, gay or bisexual 26 (7.6%) 15 (6.6%) 11 (9.7%)
Other 7 (2.1%) 3 (1.3%) 4 (3.5%)
Employed 269 (74.5%) 184 (76.3%) 85 (70.8%) χ2= 1.28; p= 0.30
Comorbid LTC 61 (17.1%) 41 (17.3%) 20 (16.7%) χ2= 0.01; p= 0.93
Taking psychotropic medication 158 (43.8%) 99 (41.1%) 59 (49.2%) χ2= 2.04; p= 0.18
M.I.N.I.7.0.2 diagnosis 290 (80.3%) 193 (80.1%) 97 (80.8%) χ2= 0.03; p= 0.89
Major depressive disorder 189 (52.4%) 125 (51.9%) 64 (53.3%) χ2= 0.07; p= 0.82
Anxiety disorder(s) 231 (64.0%) 156 (64.7%) 75 (62.5%) χ2= 0.17; p= 0.73
Generalized anxiety disorder 199 (55.1%) 134 (55.6%) 65 (54.2%) χ2= 0.07; p= 0.82
Social anxiety disorder 63 (17.5%) 42 (17.4%) 21 (17.5%) χ2= 0.00; p= 0.99
Panic disorder 61 (16.9%) 42 (17.4%) 19 (15.8%) χ2= 0.14; p= 0.70
Comorbid depressive and anxiety disorder 130 (36.0%) 88 (36.5%) 42 (35.0%) χ2= 0.08; p= 0.82
PHQ-9, Mean (SD) 14.3 (5.0) 14.4 (4.9) 14.2 (5.1) t(359)= 0.40; p= 0.68
GAD-7, Mean (SD) 12.6 (4.5) 12.7 (4.7) 12.5 (4.2) t(359)= 0.24; p= 0.80
WSAS, Mean (SD) 18.0 (7.4) 17.4 (7.2) 19.4 (7.8) t(359)=−2.48; p= 0.01
LTC long-term condition, M.I.N.I.7.0.2 Mini International Neuropsychiatric Interview, PHQ-9 Patient Health Questionnaire, GAD-7 Generalised Anxiety
Questionnaire, WSAS Work and Social Adjustment scale.
D. Richards et al.
4
npj Digital Medicine (2020)    85 Scripps Research Translational Institute
cost-savings. Short comparative trial time-horizons, which are
often associated with waiting-list designs due to ethical reasons
when with-holding care for longer-periods, limit potential QALY
gains which are time dependent (i.e. more potential for QALY
gains over 12 months relative to 8 weeks). Thus, a statistical
extrapolation of costs and outcomes in the control were used to
predict potential cost-effectiveness beyond 8-weeks, which
suggested much higher probabilities of cost-effectiveness (i.e.
>91% at £30,000 per QALY over 12 months) driven by the
sustained health improvement observed in the intervention-arm
than predicted in the control. These findings support the potential
for internet-delivered interventions to be a cost-effective comple-
ment to established interventions when assessing cost-
effectiveness beyond the 8-week treatment period11. Decision
makers wanting to use the results from the scenario analyses
based on the statistical extrapolation should first consult the
extended discussion and exploration of the scenario analyses and
what these results represent in Supplementary (section 4). The
results align with previous findings from economic evaluations of
e-health interventions in different settings, which support the
potential of iCBT to be a cost-effective complement to established
interventions11,18.
Although there was a low estimated probability of cost-savings
from a health and social care perspective, this aligns with evidence
from previous studies. Effective treatments of depression (in
particular) tend to show an increase in ‘direct’ costs (e.g.
intervention, hospital, primary care), with cost-savings often
associated with decreased ‘indirect’ costs (e.g. lost productivity
from absenteeism and presenteeism)19. Our costing perspective
(as per the NICE reference case) does not account for wider
societal costs and so does not capture these cost aspects.
Participants use of the interventions were similar to that
observed in a previous trial of the same platform (i.e. around 5 h
of usage and 14.7 logins), which also produced positive outcomes
compared to a waiting-list group16. These results align with
previous literature of iCBT, where it has been found that users do
not need to complete all the intervention to benefit from it20,21. In
this regard, there should be a shift in how adherence, and
implicitly attrition, to iCBT is conceptualised, from a more
traditional conceptualisation of completing all the modules,
towards determining how much exposure is enough to produce
clinical benefits20.
The execution of the trial within an IAPT service where iCBT is
currently used as per normal service procedures is a key strength
of the study, since it increases the ecological validity of the
findings, by utilizing a real-world context22. In addition, the service
population where we undertook the study has socio-demographic
and clinical characteristics which are representative of the overall
IAPT population, although female gender was slightly over
represented compared to IAPT reports (70% females in this trial
vs. 65% in IAPT referrals)8. The addition of clinician-administered
Fig. 2 Estimated marginal means and confidence intervals (CI) for time by treatment group interaction effects at 8-weeks. a Random
intercept linear mixed model suggesting significant time by intervention-arm interaction effect. Bonferroni adjusted estimated mean
difference between intervention-arms at 8-weeks 2.52 (95% CI 0.78, 4.27, p= 0.0009). Between group effect size d= 0.55 (95% CI 0.32, 0.77).
b Random intercept linear mixed model suggesting significant time by intervention-arm interaction effect. Bonferroni adjusted estimated
mean difference between intervention-arms at 8-weeks 2.67 (95% CI 1.07, 4.26, p= 0.0001). Between group effect size d= 0.63 (95% CI 0.40, 0.85).
c Random intercept linear mixed model suggesting significant time by intervention-arm interaction effect. Bonferroni adjusted estimated mean
difference between intervention-arms at 8-weeks 4.68 (95% CI 2.11, 7.24, p < 0.0001). Between group effect size d= 0.35 (95% CI 0.13, 0.57).
Table 2. Observed and estimated marginal means across time-points
and by treatment group.
Treatment group Waitlist control group
Observed Estimated Observed Estimated
N Mean SD Mean SE N Mean SD Mean SE
Baseline
PHQ-9 241 14.41 4.94 14.41 0.35 120 14.18 5.11 14.18 0.49
GAD-7 241 12.66 4.69 12.66 0.31 120 12.54 4.18 12.54 0.44
WSAS 241 17.35 7.15 17.30 0.50 120 19.38 7.81 19.30 0.71
8-weeks
PHQ-9 198 9.28 5.94 9.24 0.37 91 11.58 5.67 11.76 0.54
GAD-7 198 8.2 5.31 8.18 0.34 91 10.79 5.12 10.85 0.49
WSAS 198 12.71 8.31 12.60 0.54 91 16.89 8.60 17.30 0.80
3-month
PHQ-9 186 8.17 5.69 8.76 0.41
GAD-7 186 7.38 5.32 7.95 0.38
WSAS 186 11.77 8.29 12.22 0.57
6-months
PHQ-9 182 7.16 5.82 7.71 0.40
GAD-7 182 6.93 5.52 7.35 0.38
WSAS 182 10.34 8.77 10.91 0.59
9-months
PHQ-9 177 6.81 5.71 7.07 0.41
GAD-7 176 6.48 5.14 6.72 0.37
WSAS 177 9.98 8.67 10.23 0.61
12-months
PHQ-9 173 6.79 5.54 6.62 0.40
GAD-7 173 6.08 4.81 6.01 0.36
WSAS 173 10.01 8.54 9.87 0.61
Estimated marginal means in the intervention-arm at 8-weeks are based on
8-week linear mixed models. Estimated means at 3-, 6-, 9-, and 12-months
follow-up are based on follow-up marginal models.
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psychiatric interviews, alongside the self-reported clinical assess-
ments (i.e. PHQ-9, GAD-7, WSAS) increases the study’s clinical
validity. The assessment of cost-effectiveness of iCBT within a
stepped-care model (i.e. IAPT), despite the observed CEA being
limited to 8-weeks is another strength of the study.
This study also has several limitations. First, the impossibility of
following-up the waiting-list group for ethical reasons prevents
observed analysis of treatment effects and cost-effectiveness
results beyond 8-weeks; however, the maintained iCBT treatment
effect (relative to baseline) and scenario CEA suggests promising,
positive long-term outcomes (see also Supplementary section 4,
for an extended discussion around the scenario analyses). Second,
a waiting-list comparator was used instead of care as usual or an
active comparator, which would be more reflective of what usually
would happen in the absence of this iCBT intervention.
Furthermore, the use of a WL group might also produce an
overestimation of the treatment effects, since research has shown
larger effects sizes in favour of this type of control group when
compared to treatment as usual comparators12. Despite being
common in anxiety research on psychological interventions, there
are also other inherent issues with wait-list comparators such as
issues of expectancy23.
Third, inter-rater reliability for the M.I.N.I.7.0.2. was not assessed
in this study which calls into question the internal validity of the
results, although the high coefficients observed in validation
studies of the M.I.N.I. and the training and supervision provided to
the PWPs who were involved ensured that they properly
administered the interview. Fourth, asking participants to self-
report resource-use over the past three months using the CSRI
might have produced recall errors and subsequent recall-bias.
Fifth, the fact that the trial was conducted within routine care
settings caused that some users were still in treatment by the end
of the 8-week period, which could have influenced the effects of
the intervention at this timepoint. Sixth, although support was
stated on the protocol to be offered online, some reviews were
conducted over the phone (as per service-related reasons). Future
secondary analyses will explore potential confounding effects of
telephone reviews further. Finally, the study was powered to
detect between-groups differences based on F-tests; however,
after powering the study but before trial completion and
unblinding of the data, it was decided to apply linear mixed
models, since they are more robust analyses (see “Supplementary
Methods”). Post-hoc power analyses for the primary outcomes
indicated power to have been in excess of the assumed 80% and
therefore adequate in detecting moderate between-groups effect
sizes for the primary outcomes.
Limitations related to the CEA include that the predicted costs
and effects beyond 8-weeks for waiting-list control account for the
intervention’s treatment effect, which potentially underestimates
the QALYs gained and cost-differences between trial-arms. Trial
comparisons against waiting-list controls tend to estimate higher
intervention-related QALY gains than against ‘active’ controls (e.g.
face-to-face CBT), which limits the findings of this study compared
to other active interventions (e.g. other delivery methods of CBT).
Increased productivity could well be a source of cost-savings from
this iCBT intervention which can’t, or are unlikely to, be observed
in our CEA given the costing perspective and short trial time-
horizon. We applied a mean intervention cost to all participants,
rather than costing the intervention to the specific participant,
due to the inability to retrospectively link specific PWPs to trial
participants which will have an effect on how the uncertainty
around the intervention cost is accounted for in the bootstrap
replicates and subsequent CEAC.
Given that we compared iCBT to a waiting-list group in IAPT, it
would be valuable for future studies to examine the relative
efficacy of iCBT compared to other low-intensity interventions
offered within IAPT (i.e. guided self-help, psychoeducational
groups). Furthermore, a trial analysing effectiveness and cost-
effectiveness of iCBT compared to face to face CBT would shed
more light into the potential of iCBT to produce cost-savings and
thus make further recommendations on service funding and
delivery. To complement quantitative findings, we included
qualitative interviews examining the facilitators and barriers that
affected the implementation of the current intervention in IAPT
services and these will be published separately. Distinct support
models (for example support-on-demand) could shed light on the
role of the supporter within a stepped-care model. Usage and
engagement metrics, more easily measurable within an iCBT
modality, can add to the understanding of the therapeutic
process.
The results of the current study, conducted within a routine,
NHS IAPT setting, show statistically significant and sustained
reduction in depression and anxiety severity which translated into
QALY-based health improvements, considered cost-effective by
criteria typically used by NICE (albeit against a waiting-list control)
when assessed beyond the 8-week treatment period. These results
consolidate iCBT for depression and anxiety as an effective
treatment alternative within stepped-care models. The results of
this trial support the findings observed in trials from other
countries where iCBT was implemented and assessed as part of
stepped care and collaborative care models24,25. In a society
where the prevalence for depression and anxiety is rising and
demand is outpacing what mental health services are able to offer,
embedding digital interventions as treatment alternatives
increases accessibility and service efficiency, which has the
potential to be cost-effective for the health care system.
Fig. 3 Intervention-arm estimated marginal means and confidence intervals (CI) across all time-points (in months). a Marginal linear
model showing estimated mean PHQ-9 score reductions across all timepoints. Bonferroni adjusted estimated mean difference between
8-weeks and (i.e. 2 months) and 12-months 3.12; SE= 0.44; 95% CI 1.82, 4.39; p < 0.0001). b Marginal linear model showing estimated mean
PHQ-9 score reductions across all timepoints. Bonferroni adjusted estimated mean difference between 8-weeks and (i.e. 2 months) and
12-months 2.60; SE= 0.40; 95% CI 1.43, 3.76; p < 0.0001). c Marginal linear model showing estimated mean PHQ-9 score reductions across all
timepoints. Bonferroni adjusted estimated mean difference between 8-weeks and (i.e. 2 months) and 12-months 3.24; SE= 0.62; 95% CI 1.40,
5.07; p < 0.0001).
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METHOD
Study design
An 8-week randomized controlled trial (RCT) with 2:1 (iCBT intervention:
waiting-list control) allocation, and 12-month follow-up in the intervention-
arm. This study uses a pragmatic design where the trial procedures were
built around the standard service procedures used at step 2 of IAPT and
the support was offered by service employees. The study setting was an
NHS IAPT Trust in England (i.e., a local health service provider covering the
population within a geographical area). At Step 2 IAPT offers low-intensity
psychological interventions to individuals experiencing mild to moderate
symptoms of depression and anxiety. The trial protocol26 was approved by
the National Health Service (NHS) England Research Ethics Committee
(REC Reference: 17/NW/0311). The trial was prospectively registered:
Current Controlled Trials ISRCTN91967124; Clinicaltrials.gov Identifier:
NCT03188575. See “Supplementary Methods” for declarations of protocol
deviations and measures reported.
Participants
Participants were chosen based on IAPT standard operating procedures to
best represent participants who may be eligible and require iCBT as part of
usual IAPT care. Participants were new IAPT referrals, included if aged
between 18–80 years, screened for psychological pathology using clinical
thresholds for Patient-Health Questionnaire-9 (PHQ-9 ≥ 9)27 and/or Gen-
eralised Anxiety Disorder-7 (GAD-7 ≥ 8)28, and suitable for iCBT (i.e. willing
to engage in iCBT, internet access). Exclusion criteria included: suicidal
ideation/intended (PHQ-9 question 9 score > 2 and/or expressed during
clinical interview); psychotic illness; organic mental health disorder; alcohol
and/or drug misuse; and currently receiving psychological treatment.
Recruited participants signed informed consent via digital signature.
Randomization and masking
Participants were randomized at an individual level using an algorithm
developed by a computer scientist (Sealed Envelope, 2016) and executed
independently of the research team, employing random permuted blocks
using block sizes of 9, and including stratification within a 2:1 allocation
ratio between treatment and waiting list control groups. The Psychological
Wellbeing Practitioners (PWP) who carried out the support and assessment
of the patients could not be blinded to allocation for practical reasons.
Procedures
As per routine practice, clients attending the IAPT service received an
assessment of their needs which determined their initial presentation
(depression/anxiety), suitability for Step 2 and for iCBT, and allocation to
one of the available programmes. Subsequently, eligible participants were
invited to the trial and thereafter, as part of this research trial, signed
informed consent via digital signature, completed the baseline research
assessments and completed the M.I.N.I.7.0.2 with a PWP to determine a
primary diagnosis of depression or anxiety with initial treatment assign-
ment as per routine service’s practice (most suitable intervention based on
their symptomology). Given the higher prevalence of anxiety disorders
compared to depression29, primary diagnosis was used for randomization
to ensure a balanced sample; this data will inform future secondary
analyses. Those randomized to the intervention-arm commenced their
treatment with their PWP supporter.
The iCBT programs were SilverCloud Health’s ‘Space from Depression’,
‘Space from Anxiety’ and ‘Space from Depression and Anxiety’ interventions,
whose efficacy has been previously supported16 and which have been
described in detail elsewhere26. The interventions share core CBT content
with customisations for depression and specific anxiety-disorder presenta-
tions (e.g., social anxiety, generalized anxiety, panic disorder, etc.).
Participants were supported during their iCBT treatment by PWPs, who
are psychology graduates specifically trained in the provision of low-
intensity CBT interventions5. PWPs were located in offices across several
localities in the area, which are separate to primary care premises.
Assessment and triage for services typically occurs over the phone but can
sometimes occur in face-to-face settings. PWPs assessed participants for
suitability, assigned participants to a specific iCBT programme, monitored
their progress throughout the trial and provided regular reviews. During
the reviews, PWPs provided feedback to clients based on their work from
week-to-week (e.g. modules completed, tools used, shared journal entries)
and encouragement in order to promote meaningful engagement with the
programme30. PWPs were instructed to provide six online reviews (15min
per participant per review) over the 8-week intervention period. Potential
risk to participants was monitored in line with routine service procedures
(see protocol for full description of risk management). Fidelity to the
treatment was ensured through checklists and clinical supervision offered
by case managers. Specifically, the checklist assessed if the content of the
review offered by the supporter considered the client, the tools used and
the previous levels of engagement of the client when writing the review. In
total, 176 checklists were completed that represented 85 cases with an
average of 2 supervisions per case. One-hundred-and-seventy (n= 170) of
the checklists were marked as compliant with the content of online
reviews. 6 cases were either not indicated as compliant (reason not stated)
or marked as the client not attending the session.
After 8 weeks, all participants were asked to complete relevant measures
online and the control-arm participants began treatment. Follow-up
procedures included telephone administration of the Mini International
Neuropsychiatric Interview 7.0.2 (M.I.N.I.7.0.2)31 at 3-month; the timeframe
was decided in order to allow enough time for the intervention to have an
Fig. 4 CEAC representing probability of cost-effectiveness of iCBT relative to waiting-list control over 8 weeks, and predicted over 6, 9,
and 12 months. ITT Intention-to-treat, BA Baseline-Adjusted; QALY Quality-Adjusted Life year.
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effect (8 weeks), plus one month that is required by diagnostic criteria for
some disorders (e.g. panic disorder, social anxiety disorder) to be
asymptomatic in order to meet the criteria. Thereafter, online self-
reported measures were administered at 3-, 6-, 9-, and 12-month follow-
up timepoints. In order to enhance retention of participants for research
purposes only, participants received financial incentives in the form of
vouchers (up to £97.50) for the completion of research measures
(“Supplementary Methods”). For trial purposes, PWPs were formally trained
in the procedures they would be undertaking that were outside of normal
service (i.e. diagnostic interview, checking for consent, monitoring fidelity).
Outcomes
The primary outcome measures were the PHQ-9 for depressive symp-
toms27 and the GAD-7 for anxiety symptoms28.
Secondary outcomes included rates of ‘significant improvement’ and
‘recovery’, based on PHQ-9 and GAD-7 scores at 8-weeks. These were
calculated as follows: (a) significant improvement: a score change of PHQ-
9 ≥ 6 and/or GAD-7 ≥ 4, where the thresholds are calculated based on
Jacobson’s & Truax’s criteria for clinically significant change, provided they
do not reliably deteriorate on either measure (b) recovery: moving from
‘caseness’ (defined thresholds as set by IAPT being PHQ-9 ≥ 10 and/or
GAD7 ≥ 8) to ‘non-caseness’ (below the threshold on both measures)32. The
Work and Social Adjustment Scale (WSAS) was used to measure functional
impairment levels33. The M.I.N.I.7.0.2 was administered to determine
diagnosis of depression and/or anxiety disorder at baseline and 3-months
follow-up.
Rates of deterioration at post-treatment (increase in PHQ-9 ≥ 6 and/or
GAD-7 ≥ 4) and an increase in the number of diagnoses at 3-months were
considered as adverse events. Metrics of programme usage such as time
spent in the platform, number of logins and percentage of programme
completion were collected for those participants assigned to the
iCBT group.
Cost-effectiveness analysis was based on the preference-based EuroQoL
Five-Dimension Five-Level (EQ-5D-5L)34 health status measure using the
EQ-5D-5L cross-walk algorithm as NICE’s interim-position34,35 for ‘cost per
quality-adjusted life year (QALY)’ analysis. An adapted Client Service
Receipt Inventory (CSRI; routinely completed at study site, see supple-
mentary Fig. 1)36 was used to collect self-reported care resource-use over
the past 3 months (note, the CSRI at 8-weeks asked about resource-use
over the past 3 months, rather than previous 8 weeks as intended, and was
not administered at 3-month follow-up).
Measures were administered at baseline and 8-weeks forming the
primary endpoint between trial-arms, with further intervention-arm follow-
up at 3-, 6-, 9-, and 12-month. At baseline, demographic details were
collected.
Statistical analysis
Sample size was determined separately for primary presentations of
depression and anxiety. In total, 360 participants were required to detect a
moderate between-group effect size (d= 0.5) on repeated-measures for
PHQ-9 and GAD-7, based on F-tests, with a two-tailed α of .05, power of
80%, and 2:1 randomisation procedure (to reduce likelihood of having
many people waiting). The expected between-group difference and an
aggregated 25% uplift to ameliorate against attrition were based on a
previous study and a meta-analysis of iCBT for depression16,37. Due to a
discrepancy between the original formula for statistical power, based on F-
tests, and the statistical analysis actually applied (i.e. linear mixed models;
“Supplementary Methods”), statistical power of the mixed effects models
was checked through the R package nlmeU and it was found adequate.
Baseline demographic and outcome variable differences between
groups, and measure responders versus non-responders, were investigated
through Chi-squared, Mann-Whitney and t-tests. Missing data mechanisms
were assessed separately at 8-weeks (across and within trial-arms) and
throughout follow-up (intervention-arm only), using Little’s ‘missing
completely at random’ (MCAR) test. Missing data was deemed to be
‘MCAR’ at 8-weeks (see Supplementary Table 3). Across follow-up, data was
deemed to be ‘missing at random (MAR)’ (see Supplementary Table 4).
Linear mixed and marginal models were used to evaluate intervention
effectiveness, both considered robust intention-to-treat (ITT) analyses.
Analyses included all available data from all participants. Graphical and
statistical checks were conducted to assess model assumptions. These
checks did not flag any major violations of assumptions. Six models were
built, one up to 8-weeks across arms (‘8-week model’) and one including all
intervention-arm data (‘follow-up model’) per outcome variable (PHQ-9,
GAD-7, and WSAS). 8-week models were random intercept linear mixed
models and included maximum likelihood estimation. Follow-up models
were marginal models with an unstructured correlation structure as these
produced superior model fit than corresponding linear mixed models.
Given marginal model assumptions and MAR data at follow-up, follow-up
analyses were preceded by multiple-imputation via multilevel joint
modelling38,39. Bonferroni adjusted paired comparisons based on esti-
mated marginal means were conducted to explore change between time-
points and differences between the intervention-arms, and any subgroups.
Between-group Cohen’s d effect sizes were calculated utilising raw score
standard deviations40. Analyses were conducted in IBM SPSS version 26
and R version 3.6.1 using the ‘nlme’, ‘nlmeU’, ‘mitml’, ‘geepack’ and
‘emmeans’ packages.
Cost-effectiveness analysis
Cost-effectiveness analyses were based on NICE’s reference case41 from a
health and social care perspective, with QALYs elicited using the area
under the curve (AUC) method42 from the EQ-5D-5L cross-walk algorithm
as NICE’s interim-position34,35. Application of unit costs for 2017/18 in
Great British Pounds (GBP, £) to per patient resource-use to estimate
intervention and downstream costs is described in Supplementary Tables
14 and 15.
The CEA were conducted on a complete-case (CC) and ITT basis, with
missing cases imputed for the latter using multiple-imputation by chained
equation (MICE) for MAR data43. Incremental mean-point estimates of
mean cost differences (intervention minus control) over mean QALY
differences between trial-groups was used to determine incremental cost-
effectiveness ratios (ICERs). Baseline adjustments (BA) were made using
ordinary least squares (OLS) regression models with covariates including
trial-group and: (1) 3-months pre-baseline costs for costs; (2) baseline EQ-
5D-5L cross-walk score for QALYs; with both unadjusted and adjusted
estimates reported to aid transparency in the reported results43. Non-
parametric bootstrapping was used to calculate bootstrapped 95%
confidence intervals (bCIs) and standard errors (bSE) around costs and
effects, and for plotting cost-effectiveness acceptability curves (CEACs).
CEACs present the probability of intervention cost-effectiveness compared
to control across a range of decision maker willingness-to-pay (WTP)
thresholds e.g. NICE’s £20,000 to £30,000 per QALY thresholds41.
The base-case CEA is conducted over the initial 8-weeks. As part of
scenario analyses, regression-based extrapolations were used to estimate
QALYs and costs beyond 8-weeks for the waiting-list control. In the ITT
dataset for the intervention-arm, OLS models were fitted to the (EQ-5D-5L)
tariff score/(downstream) costs at 3 (not for costs), 6, 9 and 12 months as
the response variable, independently, and tariff score/costs at baseline and
8 weeks as the explanatory variables. The predicted models were then
fitted to the waiting-list control’s data to estimate their potential tariff
score/costs at the aforementioned time-points from which total costs and
QALYs could be estimated, and CEA conducted. A step-by-step guide
describing the scenario analyses is provided in Supplementary (section 4).
Analyses were conducted in Stata version 15.
Data Monitoring and Trial Managing Committee
The Data Monitoring and Trial Managing Committee (DMTMC) was
composed of the following personnel: the SilverCloud data manager and
two trial managers, Berkshire NHS representatives including the PI and Co-
PI at Berkshire, two R&D clinician research assistants, and two R&D research
assistants. The DMTMC met weekly and minutes were recorded at each of
these meetings. Each week participants progress was monitored for safety
and routine clinical decisions e.g. stepping up a participant from low-
intensity to high-intensity treatment were communicated to the DMTMC
and recorded (see consort flow diagram). To ensure the validity and
integrity of the data collected throughout the trial period, the data
manager provided weekly progress reports to the DMTMC.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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